ASCO in Review: Oncologists See Practice-Changing, Affirming Data

The 2023 American Society of Clinical Oncology (ASCO) meeting had implications for patients, physicians and biopharma companies. AstraZeneca’s Tagrisso (osimertinib) demonstrated its worth in EGFR-mutated non-small cell lung cancer, Novartis’ Kisqali impressed oncologists in early breast cancer, Merck’s Keytruda outpaced Astra’s Imfinzi in the perioperative NSCLC setting, and Moderna and Merck released more promising results for their personalized cancer vaccine.